Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Biogen posts Phase 4 RESPOND results for nusinersen after onasemnogene abeparvovecOct 30Trial updateBiogennusinersen
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Biogen posts Q2 2026 results, sets five late-stage readouts over next four quartersJul 29Quarterly updateBiogenfelzartamab